Scinovex
articleTop 1% cited

The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine

Molecular Psychiatry · 2006 · Vol. 11(7) · pp. 680–684
Norbert MüllerMarkus SchwarzSandra DehningA. DouheAnja CeroveckiB. Goldstein-MüllerIlja SpellmannGuenter HetzelKatja MainoNikolaus KleindienstH-J MöllerVolker AroltMichael Riedel
Treatment of Major DepressionTryptophan and brain disordersStress Responses and CortisolReboxetineCelecoxibPlaceboCyclooxygenasePharmacologyMedicineDepression (economics)Randomized controlled trialPsychologyPsychiatry

MeSH terms

CelecoxibReboxetineAdultAntidepressive AgentsDepressive DisorderDouble-Blind MethodDrug Therapy, CombinationFemaleHumansInflammationLorazepamMaleMiddle AgedMorpholinesPatient Dropouts
Citations
791
FWCI
23.64
field-weighted impact
References
38
Percentile
100%
vs. same field & year
Citations per year
References
Cytokine Production and Treatment Response in Major Depressive Disorder
Neuropsychopharmacology · 2000 · 729 citations
A RATING SCALE FOR DEPRESSION
Journal of Neurology Neurosurgery & Psychiatry · 1960 · 32,326 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine · Scinovex